Krystal Biotech, Inc. KRYS Interest Income (Expense), Nonoperating
Interest Income (Expense), Nonoperating at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s interest income (expense), nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s interest income (expense), nonoperating?
- Krystal Biotech, Inc. (KRYS) reported interest income (expense), nonoperating of $7.75M in Q1 2026.
- How has Krystal Biotech, Inc.'s interest income (expense), nonoperating changed year-over-year?
- Krystal Biotech, Inc.'s interest income (expense), nonoperating increased by 5.6% year-over-year, from $7.35M to $7.75M.
- What is the long-term trend for Krystal Biotech, Inc.'s interest income (expense), nonoperating?
- Over 2 years (2022 to 2025), Krystal Biotech, Inc.'s interest income (expense), nonoperating has grown at a 132.7% compound annual growth rate (CAGR), from $5.22M to $28.27M.